These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 638885)

  • 1. Hemostatic changes induced by exercise during oral contraceptive use.
    Hedlin AM; Milojevic S; Korey A
    Can J Physiol Pharmacol; 1978 Apr; 56(2):316-20. PubMed ID: 638885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator levels in plasma and urine during exercise and oral contraceptive use.
    Hedlin AM; Milojevic S; Korey A
    Thromb Haemost; 1978 Jun; 39(3):743-50. PubMed ID: 705703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
    Wilson ES; Cruickshank J; McMaster M; Weir RJ
    Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity.
    Howie PW; Mallinson AC; Prentice CR; Horne CH; McNicol GP
    Lancet; 1970 Dec; 2(7687):1329-32. PubMed ID: 4098907
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptives, lipoproteins, and atherosclerosis.
    Adams MR; Clarkson TB; Shively CA; Parks JS; Kaplan JR
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1388-93. PubMed ID: 2220963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral contraceptive agents on copper and zinc balance in young women.
    Crews MG; Taper LJ; Ritchey SJ
    Am J Clin Nutr; 1980 Sep; 33(9):1940-5. PubMed ID: 7416062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
    Petersen KR; Sidelmann J; Skouby SO; Jespersen J
    Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):32-8. PubMed ID: 8420344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemostatic balance during treatment with the newest contraceptives].
    Petersen KR; Skouby SO; Sidelmann J; Jespersen J
    Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical basis for the "riboflavin defect" associated with the use of oral contraceptives. A study in female rats.
    Ahmed F; Bamji MS
    Contraception; 1976 Sep; 14(3):297-307. PubMed ID: 10133
    [No Abstract]   [Full Text] [Related]  

  • 13. Change in glucose and insulin after six months' treatment with the oral contraceptive Demulen.
    Spellacy WN; Buhi WC; Birk SA; McCreary SA
    Am J Obstet Gynecol; 1974 May; 119(2):266-7. PubMed ID: 4823395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demulen: hastily approved drug.
    Goldberg DC
    Science; 1970 Oct; 170(3957):491. PubMed ID: 4918764
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
    Jespersen J; Petersen KR; Skouby SO
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):396-403. PubMed ID: 2196812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
    Misz M; Beck P
    Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of blood coagulation parameters.
    Newman RL; Sirridge M; Brinkman M; Shannon R
    Am J Obstet Gynecol; 1976 May; 125(1):108-14. PubMed ID: 775991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel.
    Sabra A; Bonnar J
    J Reprod Med; 1983 Jan; 28(1 Suppl):85-91. PubMed ID: 6834350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood coagulation and fibrinolysis in women receiving estrogen, gestagen and estrogen-gestagen-contraceptives (author's transl)].
    Lechner K; Hartmann E; Schneider WH; Spona J; Matt K
    Klin Wochenschr; 1976 May; 54(9):431-8. PubMed ID: 1271696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.